JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 379.59 Billion KRW | -5.62% |
| 2022 | 402.21 Billion KRW | -9.52% |
| 2021 | 444.51 Billion KRW | 30.12% |
| 2020 | 341.61 Billion KRW | -0.44% |
| 2019 | 343.11 Billion KRW | 2.83% |
| 2018 | 333.68 Billion KRW | -7.34% |
| 2017 | 360.09 Billion KRW | -3.91% |
| 2016 | 374.76 Billion KRW | -3.43% |
| 2015 | 388.07 Billion KRW | 4.8% |
| 2014 | 370.29 Billion KRW | -4.72% |
| 2013 | 388.62 Billion KRW | -11.57% |
| 2012 | 439.48 Billion KRW | -11.54% |
| 2011 | 496.84 Billion KRW | 44.83% |
| 2010 | 343.05 Billion KRW | 10.56% |
| 2009 | 310.28 Billion KRW | 27.41% |
| 2008 | 243.53 Billion KRW | 37.23% |
| 2007 | 177.46 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 382.18 Billion KRW | 0.68% |
| 2024 Q2 | 380.41 Billion KRW | -0.46% |
| 2023 Q1 | 437.38 Billion KRW | 8.74% |
| 2023 Q2 | 385.11 Billion KRW | -11.95% |
| 2023 FY | 379.59 Billion KRW | -5.62% |
| 2023 Q3 | 422.64 Billion KRW | 9.74% |
| 2023 Q4 | 379.59 Billion KRW | -10.19% |
| 2022 Q4 | 402.21 Billion KRW | -4.89% |
| 2022 Q2 | 432.25 Billion KRW | -2.93% |
| 2022 Q3 | 422.87 Billion KRW | -2.17% |
| 2022 Q1 | 445.27 Billion KRW | 0.17% |
| 2022 FY | 402.21 Billion KRW | -9.52% |
| 2021 Q3 | 385.31 Billion KRW | 0.53% |
| 2021 FY | 444.51 Billion KRW | 30.12% |
| 2021 Q1 | 329.82 Billion KRW | -3.45% |
| 2021 Q4 | 444.51 Billion KRW | 15.36% |
| 2021 Q2 | 383.27 Billion KRW | 16.21% |
| 2020 Q2 | 364.28 Billion KRW | 3.67% |
| 2020 Q1 | 351.4 Billion KRW | 2.42% |
| 2020 Q3 | 345.28 Billion KRW | -5.22% |
| 2020 Q4 | 341.61 Billion KRW | -1.06% |
| 2020 FY | 341.61 Billion KRW | -0.44% |
| 2019 Q2 | 346.65 Billion KRW | -2.48% |
| 2019 Q1 | 355.45 Billion KRW | 6.52% |
| 2019 FY | 343.11 Billion KRW | 2.83% |
| 2019 Q3 | 327.14 Billion KRW | -5.63% |
| 2019 Q4 | 343.11 Billion KRW | 4.88% |
| 2018 Q3 | 331.64 Billion KRW | -1.55% |
| 2018 Q2 | 336.86 Billion KRW | -13.22% |
| 2018 Q1 | 388.19 Billion KRW | 7.8% |
| 2018 FY | 333.68 Billion KRW | -7.34% |
| 2018 Q4 | 333.68 Billion KRW | 0.61% |
| 2017 Q3 | 361.91 Billion KRW | 0.83% |
| 2017 Q2 | 358.94 Billion KRW | -0.55% |
| 2017 Q1 | 360.93 Billion KRW | -3.69% |
| 2017 Q4 | 360.09 Billion KRW | -0.5% |
| 2017 FY | 360.09 Billion KRW | -3.91% |
| 2016 FY | 374.76 Billion KRW | -3.43% |
| 2016 Q1 | 388.87 Billion KRW | 0.21% |
| 2016 Q2 | 398.91 Billion KRW | 2.58% |
| 2016 Q3 | 360.25 Billion KRW | -9.69% |
| 2016 Q4 | 374.76 Billion KRW | 4.03% |
| 2015 Q2 | 382.44 Billion KRW | -4.48% |
| 2015 Q1 | 400.38 Billion KRW | 8.13% |
| 2015 Q4 | 388.07 Billion KRW | -1.68% |
| 2015 Q3 | 394.68 Billion KRW | 3.2% |
| 2015 FY | 388.07 Billion KRW | 4.8% |
| 2014 Q2 | 392.54 Billion KRW | 0.1% |
| 2014 Q1 | 392.15 Billion KRW | 0.91% |
| 2014 Q3 | 396.05 Billion KRW | 0.9% |
| 2014 Q4 | 370.29 Billion KRW | -6.51% |
| 2014 FY | 370.29 Billion KRW | -4.72% |
| 2013 FY | 388.62 Billion KRW | -11.57% |
| 2013 Q4 | 388.62 Billion KRW | -5.85% |
| 2013 Q3 | 412.76 Billion KRW | -2.07% |
| 2013 Q2 | 421.48 Billion KRW | -8.05% |
| 2013 Q1 | 458.37 Billion KRW | 4.3% |
| 2012 Q1 | 500.19 Billion KRW | 0.0% |
| 2012 FY | 439.48 Billion KRW | -11.54% |
| 2012 Q4 | 439.48 Billion KRW | 0.0% |
| 2011 FY | 496.84 Billion KRW | 44.83% |
| 2011 Q3 | 476.6 Billion KRW | 4.45% |
| 2011 Q1 | 467.79 Billion KRW | 36.36% |
| 2011 Q2 | 456.29 Billion KRW | -2.46% |
| 2010 Q1 | 362.48 Billion KRW | 16.82% |
| 2010 Q2 | 376.2 Billion KRW | 3.79% |
| 2010 FY | 343.05 Billion KRW | 10.56% |
| 2010 Q4 | 343.05 Billion KRW | -7.21% |
| 2010 Q3 | 369.72 Billion KRW | -1.72% |
| 2009 Q1 | 303.93 Billion KRW | 24.8% |
| 2009 Q4 | 310.28 Billion KRW | -6.4% |
| 2009 Q3 | 331.5 Billion KRW | 3.01% |
| 2009 FY | 310.28 Billion KRW | 27.41% |
| 2009 Q2 | 321.82 Billion KRW | 5.88% |
| 2008 FY | 243.53 Billion KRW | 37.23% |
| 2008 Q4 | 243.53 Billion KRW | 3.44% |
| 2008 Q3 | 235.42 Billion KRW | 8.14% |
| 2008 Q2 | 217.71 Billion KRW | 7.66% |
| 2008 Q1 | 202.22 Billion KRW | 13.95% |
| 2007 Q4 | 177.46 Billion KRW | -4.44% |
| 2007 FY | 177.46 Billion KRW | 0.0% |
| 2007 Q2 | 209.85 Billion KRW | 3.95% |
| 2007 Q1 | 201.88 Billion KRW | 0.0% |
| 2007 Q3 | 185.69 Billion KRW | -11.51% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -387.553% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 59.174% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 46.316% |
| HANDOK Inc. | 449.7 Billion KRW | 15.59% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -343.092% |
| Yuhan Corporation | 712.33 Billion KRW | 46.711% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 39.929% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -2288.239% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 55.437% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -609.15% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -84.383% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -404.98% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -156.842% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -439.192% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -387.553% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -941.815% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -51.143% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -71.993% |
| JW Holdings Corporation | 827.51 Billion KRW | 54.128% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 13.134% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 35.31% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -378.677% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -442.534% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -56.308% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -14.927% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -387.553% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 22.534% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 55.759% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 0.0% |
| Yuhan Corporation | 712.33 Billion KRW | 46.711% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 20.555% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -177.143% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 26.53% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -145.637% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -321.939% |
| CKD Bio Corp. | 170.76 Billion KRW | -122.299% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -55.743% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -140.775% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -782.394% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -378.677% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 39.986% |
| Boryung Corporation | 373.1 Billion KRW | -1.739% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -82.326% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -84.383% |
| JW Lifescience Corporation | 96.44 Billion KRW | -293.598% |